display

A problem occurred with one batch in the production of the corona vaccine by the manufacturer Johnson & Johnson.

In a production facility of a partner company, an ingredient had not passed quality control and was therefore not used, Johnson & Johnson announced on Wednesday (local time).

The error was reported to the health authority FDA and more employees are now used to monitor production.

The company did not disclose how many doses of vaccine were affected by the problem at contract manufacturer Emergent Biosolutions.

According to a report in the "New York Times" it is said to be about 15 million doses of the vaccine.

Workers at the plant that makes both J&J and AstraZeneca vaccines accidentally mixed up the ingredients in the two vaccines a few weeks ago, the paper reported.

Federal officials would attribute the error to human error, it said.

display

The company's vaccination takes full effect after just one injection.

Johnson & Johnson said it plans to continue delivering 100 million cans to the US government by the end of May, as previously promised.

The company will now provide the contract manufacturer Emergent Biosolutions with additional expertise and monitor production in the US state of Maryland on site, it said.

"Quality and safety are still our top priority," said the company.

The manufacturing facility of Emergent Biosolutions has not yet been approved by the US Food and Drug Administration (FDA) for the vaccine.

However, the company is already preparing production in order to be able to meet delivery targets.